ArticleOncology letters2026
Serum expression levels of HOTAIR and miR-646 in endometrial cancer.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometrial cancer (EC) is the fourth most common malignancy in women in high-income countries and the sixth globally, with ~417,000 new cases and ~97,370 mortalities reported worldwide in 2020. Its incidence has increased by >130% over the past 30 years, due to advances in FIGO-based staging systems and earlier detection. However effective non-invasive biomarkers for early diagnosis and staging are limited. Non-coding RNAs (ncRNAs), particularly long ncRNAs (lncRNAs) and microRNAs (miRs), are critical regulators in the biology of cancer, and may potentially serve as novel diagnostic and prognostic biomarkers. In the present study, serum levels of the lncRNA Hox antisense intergenic RNA (HOTAIR) and the miR-646 were evaluated in 71 patients with EC and 62 matched healthy controls using reverse transcription-quantitative PCR. The results showed that the serum HOTAIR expression level was significantly increased in patients with EC compared with controls. This suggested that it may have potential as a diagnostic biomarker. Although overall miR-646 levels did not differ significantly between patients with EC and healthy controls, a notable reduction in miR-646 levels were observed in patients with advanced clinical T stages compared with those with early stages. This indicated an association with disease progression. Receiver operating characteristic curve analyses indicated that a serum HOTAIR level of 1.08 may distinguish patients with EC from healthy controls with 63.3% sensitivity and 61.2% specificity. Additionally, a miR-646 cut-off value of 0.655 differentiated patients with advanced-stage from early-stage EC with 72.7% sensitivity and 66.7% specificity. These findings suggested that serum HOTAIR may be a potential diagnostic biomarker and that miR-646 may be a potential indicator of disease progression in EC. However, further validation in larger patient cohorts and investigation of exosomal expression levels are necessary in order to assess the potential clinical relevance and therapeutic potential of HOTAIR and miR-646.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.